Skip to main content
. 2017 Mar 8;12(3):e0172740. doi: 10.1371/journal.pone.0172740

Fig 4. TORC1 and TORC2 activities are not significantly changed in ste12PIKFYVE-W1037STOP.

Fig 4

(A-F) Assessment of TORC1/2 in vivo activity in steady-state EMMG cultures by immunoblotting of known previously established substrates. All antibodies and Maf1.PK have been validated previously in Du, et al 2012 and Halova et al 2013.